300 IR HDM tablet: a sublingual immunotherapy tablet for the treatment of house dust mite-associated allergic rhinitis

References

• Grabenhenrich LB, Keil T, Reich A, et al. Prediction and prevention of allergic rhinitis: a birth cohort study of 20 years. J Allergy Clin Immunol. 2015;136(4):932–40.e12.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008. Allergy. 2008;63(Suppl 86):8–160.
   PubMed Web of Science ®Google Scholar
• Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466–476.
   PubMed Web of Science ®Google Scholar
• Bjorksten B, Clayton T, Ellwood P, et al. Worldwide time trends for symptoms of rhinitis and conjunctivitis: phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol. 2008;19(2):110–124.
   PubMed Web of Science ®Google Scholar
• Canonica GW, Bousquet J, Mullol J, et al. A survey of the burden of allergic rhinitis in Europe. Allergy. 2007;62(Suppl 85):17–25.
   PubMed Web of Science ®Google Scholar
• Leger D, Annesi-Maesano I, Carat F, et al. Allergic rhinitis and its consequences on quality of sleep: an unexplored area. Arch Intern Med. 2006;166(16):1744–1748.
   PubMedGoogle Scholar
• Nolte H, Nepper-Christensen S, Backer V. Unawareness and undertreatment of asthma and allergic rhinitis in a general population. Respir Med. 2006;100(2):354–362.
   PubMed Web of Science ®Google Scholar
• Valovirta E, Myrseth SE, Palkonen S. The voice of the patients: allergic rhinitis is not a trivial disease. Curr Opin Allergy Clin Immunol. 2008;8(1):1–9.
   PubMed Web of Science ®Google Scholar
• Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc. 2007;28(1):3–9.
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol. 2011;106(2 Suppl):S12–16.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Lotvall J, Simoens S, et al. Economic burden of inadequate management of allergic diseases in the European Union: a GA2LEN review. Allergy. 2014;69(10):1275–1279.
   PubMed Web of Science ®Google Scholar
• Khan DA. Allergic rhinitis and asthma: epidemiology and common pathophysiology. Allergy Asthma Proc. 2014;35(5):357–361.
   PubMed Web of Science ®Google Scholar
• Shaaban R, Zureik M, Soussan D, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet. 2008;372(9643):1049–1057.
   PubMed Web of Science ®Google Scholar
• Calderon MA, Linneberg A, Kleine-Tebbe J, et al. Respiratory allergy caused by house dust mites: what do we really know? J Allergy Clin Immunol. 2015;136(1):38–48.
   PubMed Web of Science ®Google Scholar
• Eifan AO, Calderon MA, Durham SR. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther. 2013;13(11):1543–1556.
   PubMed Web of Science ®Google Scholar
• Batard T, Baron-Bodo V, Martelet A, et al. Patterns of IgE sensitization in house dust mite-allergic patients: implications for allergen immunotherapy. Allergy. 2016;71(2):220–229.
   PubMed Web of Science ®Google Scholar
• Newson RB, Van Ree R, Forsberg B, et al. Geographical variation in the prevalence of sensitization to common aeroallergens in adults: the GA(2) LEN survey. Allergy. 2014;69(5):643–651.
   PubMed Web of Science ®Google Scholar
• Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24(5):758–764.
   PubMed Web of Science ®Google Scholar
• Melioli G, Marcomini L, Agazzi A, et al. The IgE repertoire in children and adolescents resolved at component level: a cross-sectional study. Pediatr Allergy Immunol. 2012;23(5):433–440.
   PubMed Web of Science ®Google Scholar
• Crisafulli D, Almqvist C, Marks G, et al. Seasonal trends in house dust mite allergen in children’s beds over a 7-year period. Allergy. 2007;62(12):1394–1400.
   PubMed Web of Science ®Google Scholar
• Gelardi M, Peroni DG, Incorvaia C, et al. Seasonal changes in nasal cytology in mite-allergic patients. J Inflamm Res. 2014;7:39–44.
   PubMedGoogle Scholar
• Kosik-Bogacka DI, Kalisinska E, Henszel L, et al. Seasonal dynamics of house dust mites in dust samples collected from sleeping places in north-western Poland. Zoonoses Public Health. 2012;59(1):8–15.
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Cirillo I, Klersy C, et al. Nasal obstruction is the key symptom in hay fever patients. Otolaryngol Head Neck Surg. 2005;133(3):429–435.
   PubMed Web of Science ®Google Scholar
• Sibbald B, Rink E. Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history. Thorax. 1991;46(12):895–901.
   PubMed Web of Science ®Google Scholar
• Custovic A, Sonntag HJ, Buchan IE, et al. Evolution pathways of IgE responses to grass and mite allergens throughout childhood. J Allergy Clin Immunol. 2015;136(6):1645-1652 e1641-1648.
   Web of Science ®Google Scholar
• Simpson A, Lazic N, Belgrave DC, et al. Patterns of IgE responses to multiple allergen components and clinical symptoms at age 11 years. J Allergy Clin Immunol. 2015;136(5):1224–1231.
   PubMed Web of Science ®Google Scholar
• Calderon MA, Kleine-Tebbe J, Linneberg A, et al. House dust mite respiratory allergy: an overview of current therapeutic strategies. J Allergy Clin Immunol Pract. 2015;3(6):843–855.
   PubMed Web of Science ®Google Scholar
• Biagtan M, Viswanathan R, Bush RK. Immunotherapy for house dust mite sensitivity: where are the knowledge gaps? Curr Allergy Asthma Rep. 2014;14(12):482.
   PubMed Web of Science ®Google Scholar
• Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010;8:Cd001186.
   PubMed Web of Science ®Google Scholar
• Calderon MA, Simons FE, Malling HJ, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy. 2012;67(3):302–311.
   PubMed Web of Science ®Google Scholar
• Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7(1):6.
   PubMedGoogle Scholar
• Kaul S, May S, Luttkopf D, et al. Regulatory environment for allergen-specific immunotherapy. Allergy. 2011;66(6):753–764.
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA. House dust mite sublingual tablets (Actair®): a guide to their use as allergy immunotherapy for house dust mite-induced allergic rhinitis. Drugs Ther Perspect. 2016;32(6):219–225.
   Google Scholar
• Demoly P, Emminger W, Rehm D, et al. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized, double-blind, placebo-controlled Phase III trial. J Allergy Clin Immunol. 2016;137(2):444-451.e8.
   PubMed Web of Science ®Google Scholar
• Klimek L, Mosbech H, Zieglmayer P, et al. SQ house dust mite (HDM) SLIT-tablet provides clinical improvement in HDM-induced allergic rhinitis. Expert Rev Clin Immunol. 2016;12(4):369–377.
   PubMed Web of Science ®Google Scholar
• Shionogi Co. Ltd. Actair® house dust mite 100 IR & 300 IR sublingual tablets: Japanese prescribing information. 2016.
   Google Scholar
• Stallergenes Greer. Summary of Product Characteristics: Actair® 100 IR & 300 IR sublingual tablets. 2016 [cited 2016 Aug 14]. Available from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&k=A
   Google Scholar
• Calderon MA, Cox L, Casale TB, et al. The effect of a new communication template on anticipated willingness to initiate or resume allergen immunotherapy: an internet-based patient survey. Allergy Asthma Clin Immunol. 2015;11(1):17.
   PubMedGoogle Scholar
• Bergmann KC, Demoly P, Worm M, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol. 2014;133(6):1608–1614 e1606.
   PubMed Web of Science ®Google Scholar
• Okamoto Y, Fujieda S, Okano M, et al. House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis. Allergy. 2016. doi:10.1111/all.12996. [Epub ahead of print].
   PubMedGoogle Scholar
• Pitsios C, Demoly P, Bilo MB, et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy. 2015;70(8):897–909.
   PubMed Web of Science ®Google Scholar
• Moingeon P. Progress in the development of specific immunotherapies for house dust mite allergies. Expert Rev Vaccines. 2014;13(12):1463–1473.
   PubMed Web of Science ®Google Scholar
• Chapman MD, Wunschmann S, Pomes A. Proteases as Th2 adjuvants. Curr Allergy Asthma Rep. 2007;7(5):363–367.
   PubMed Web of Science ®Google Scholar
• Trompette A, Divanovic S, Visintin A, et al. Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. Nature. 2009;457(7229):585–588.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP), Guideline on Allergen Products: Production and Quality Issues (CHMP/BWP/304831/2007). 2007.
   Google Scholar
• Batard T, Hrabina A, Bi XZ, et al. Production and proteomic characterization of pharmaceutical-grade Dermatophagoides pteronyssinus and Dermatophagoides farinae extracts for allergy vaccines. Int Arch Allergy Immunol. 2006;140(4):295–305.
   PubMed Web of Science ®Google Scholar
• Moingeon P, Batard T, Nony E, et al. Quality control of house dust mite extracts for allergen immunotherapy. Int Arch Allergy Immunol. 2013;161(3):285–286.
   PubMed Web of Science ®Google Scholar
• Roux M, Devillier P, Yang WH, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts: results of a dose-ranging study in an environmental exposure chamber. J Allergy Clin Immunol. 2016;138(2):451–458.e455.
   PubMed Web of Science ®Google Scholar
• Moingeon P. Update on immune mechanisms associated with sublingual immunotherapy: practical implications for the clinician. J Allergy Clin Immunol Pract. 2013;1(3):228–241.
   PubMed Web of Science ®Google Scholar
• Baron-Bodo V, Batard T, Nguyen H, et al. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy. Clin Exp Allergy. 2012;42(10):1510–1518.
   PubMed Web of Science ®Google Scholar
• Tourdot S, Airouche S, Berjont N, et al. Evaluation of therapeutic sublingual vaccines in a murine model of chronic house dust mite allergic airway inflammation. Clin Exp Allergy. 2011;41(12):1784–1792.
   PubMed Web of Science ®Google Scholar
• Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy. 2009;64(Suppl 91):1–59.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP), Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases (CHMP/EWP/18504/2006). 2008.
   Google Scholar
• Bagnasco M, Mariani G, Passalacqua G, et al. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. J Allergy Clin Immunol. 1997;100(1):122–129.
   PubMed Web of Science ®Google Scholar
• Bagnasco M, Morbelli S, Altrinetti V, et al. Allergen biodistribution in humans. Chem Immunol Allergy. 2003;82:33–43.
   PubMedGoogle Scholar
• Halken S, Wahn U, Mélac M, et al. Assessment of efficacy and safety of sublingual tablets of house dust mite allergen extract in children and adolescents with allergic rhinitis. Clin Transl Allergy. 2014;4(Suppl. 1):017.
   Google Scholar
• Demoly P, Meziane L, Le Gall M, et al. Safety and tolerability of house dust mite tablets in sublingual immunotherapy. J Allergy Clin Immunol. 2008;121(2 (Suppl. 1)):S128.
   Google Scholar
• Roux M, Patel P, Viatte A, et al. Safety of high doses of sublingual tablets of house dust mite allergen extracts in adolescents with allergic rhinitis. Allergy Eur J Allergy Clin Immunol. 2014;69:613.
   Google Scholar
• Roux M, Kakudo S, Karagiannis E, et al. Efficacy of sublingual tablet of house dust mite allergen extracts in adolescents with house dust mite-associated allergic rhinitis. Presented at: 4th Pediatric Allergy and Asthma Meeting (PAAM); Berlin; 2015.
   Google Scholar
• Okamoto Y, Masuyama K, Fujieda S, et al. House dust mite tablet (S-524101/STG320) at 300 IR is effective in both mono and poly-sensitized patients with allergic rhinitis in a Phase 2/3 study conducted in Japan. Presented at: European Academy of Allergy and Clinical Immunology Congress (EAACI) 2016; Vienna; 2016.
   Google Scholar
• Parkes A, Abiteboul K. Treatment with house dust mite tablets for sublingual immunotherapy: relationship between allergic disease severity and efficacy in a confirmatory study. Intern Med J. 2016;46(S4):21.
   Web of Science ®Google Scholar
• Demoly PM, Bergmann KC, Khairallah S, et al. Safety of STG320 sublingual tablets of house dust mite allergen extracts in subjects with HDM-associated allergic rhinitis: results of a pooled analysis. J Allergy Clin Immunol. 2016;137(2 Suppl):AB403.
   Google Scholar
• Parkes A, Cognet-Sicé J, Okamoto Y. Safety of 300IR sublingual tablet of house dust mite allergen extracts in adolescents with house dust mite-associated allergic rhinitis. Intern Med J. 2016;46(S4):20.
   Google Scholar
• Demoly P, Passalacqua G, Calderon MA, et al. Choosing the optimal dose in sublingual immunotherapy: rationale for the 300 index of reactivity dose. Clin Transl Allergy. 2015;5:44.
   PubMed Web of Science ®Google Scholar
• Bahceciler NN, Babayigit Hocaoglu A, Galip N. A milestone in house dust-mite-allergen immunotherapy: the new sublingual tablet S-524101 (Actair). Expert Rev Vaccines. 2014;13(12):1427–1438.
   PubMed Web of Science ®Google Scholar
• Demoly P, Betting P, Le Gall M, et al. Tolérance d’un comprimé sublingual d’extraits allergéniques d’acariens chez l’adulte présentant un asthme allergique aux acariens. Presented at: 9e Congrès Francophone d’Allergologie (CFA); Paris; 2014.
   Google Scholar
• Zeldin RK, Demoly P, Betting P, et al. Sublingual tablets of house dust mite allergen extracts: results of a Phase I study in adults with mite-associated allergic asthma. Eur Respir J. 2013;42(Suppl. 57):665s.
   Google Scholar
• Demoly P, Le Gall M, Roux M, et al. Safety and tolerability of high doses of sublingual tablet of house dust mite allergen extracts in subjects with house dust mite-associated respiratory allergy. Allergy. 2015;70(Suppl. 101):1–649.
   Google Scholar
• Le Gall M, Demoly PM, Rodriguez P, et al. Immunological effects of treatment with STG320 sublingual tablets of house dust mite allergen extracts in subjects with HDM-associated allergic asthma. J Allergy Clin Immunol. 2016;137(2 Suppl):AB404.
   Google Scholar